Peripheral SNCA+ cells as a poor prognostic factor for nivolumab therapy in advanced gastric cancer
These suggest that SNCA<sup>+</sup> cells are significant poor prognostic factors in nivolumab therapy for advanced GC. Targeting SNCA may be a promising strategy to improve clinical outcomes in anti-PD1/PDL1 therapy for GC.
Authors
- Hirokazu Shoji (ORCID: https://orcid.org/0000-0002-8922-5227)
- Hiroshi Imazeki
- Kei Muro
- Rika Kizawa (ORCID: https://orcid.org/0000-0003-1275-9228)
- Kengo Nagashima (ORCID: https://orcid.org/0000-0003-4529-9045)
- Naohiro Okano
- Yukiya Narita (ORCID: https://orcid.org/0000-0002-8018-0077)
- Kai Tsugaru (ORCID: https://orcid.org/0000-0001-7763-7999)
- Yoshiyuki Yamamoto (ORCID: https://orcid.org/0000-0002-2932-5904)
- Takeru Wakatsuki (ORCID: https://orcid.org/0000-0002-1463-3859)
- Takeshi Kawakami (ORCID: https://orcid.org/0000-0001-9385-9516)
- Naoki Takahashi (ORCID: https://orcid.org/0000-0001-6377-9507)
- Narikazu Boku
- Yusuke Amanuma
- Chie Kudo‐Saito (ORCID: https://orcid.org/0000-0003-4644-9404)
Institutions
- Kyorin University (JP)
- National Cancer Centre Japan (JP)
- Shizuoka Cancer Center (JP)
- Keio University Hospital (JP)
- Tokyo Medical University Hospital (JP)
- University of Tsukuba Hospital (JP)
- Chiba Cancer Center (JP)
- Saitama Cancer Center (JP)
- Aichi Cancer Center (JP)
- The Cancer Institute Hospital (JP)
- National Cancer Center Hospital East (JP)
- Toranomon Hospital (JP)
- National Cancer Research Institute (GB)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1007/s12672-025-03817-0
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Ono Pharmaceutical